Drug profile · INN
buclizine hydrochloride
BUCLADIN-S
buclizine hydrochloride (BUCLADIN-S) is a histamine h1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — buclizine hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
buclizine hydrochloride (BUCLADIN-S) is a histamine h1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Histamine H1 receptor antagonist
Primary target: Histamine H1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is buclizine hydrochloride?
buclizine hydrochloride (BUCLADIN-S) is a histamine h1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for buclizine hydrochloride?
BUCLADIN-S is a marketed brand name for buclizine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of buclizine hydrochloride?
buclizine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.